Pleural effusion formation in the course of myeloma.
Comert M etal. Arch Bronconeumol. 2015 Jan 22. pii: S0300-2896(14)00242-7. doi: 10.1016/j.arbres.2014.05.009. [Epub ahead of print].
Diagnosis of monoclonal gammopathy of renal significance.
Bridoux F et al. Kidney Int. 2015 Jan 21. doi: 10.1038/ki.2014.408. [Epub ahead of print].
Paralytic ileus following “subcutaneous bortezomib” therapy: focus on the clinical emergency-report of two cases.
Mele G et al. Clin Exp Med. 2015 Jan 20. [Epub ahead of print].
Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients.
Kamber C et al. Bone Marrow Transplant. 2015 Jan 19. doi: 10.1038/bmt.2014.290. [Epub ahead of print].
A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use.
Baird P et al. J Oncol Pharm Pract. 2015 Jan 14. pii: 1078155214568581. [Epub ahead of print].
Hematologic malignancies of the liver: spectrum of disease.
Tomasian A et al. Radiographics. 2015 Jan-Feb;35(1):71-86. doi: 10.1148/rg.351130008.
Encephalopathy following melphalan administration.
Dubey D et al. J Chemother. 2015 Jan 11:1973947814Y0000000231. [Epub ahead of print].
Brain Abscesses Caused by Nocardia paucivorans in a Multiple Myeloma Patient Treated with Lenalidomide and Dexamethasone: a Case Report and Review of Literature.
Monticelli J et al. Mediterr J Hematol Infect Dis. 2015 Jan 1;7(1):e2015011. doi: 10.4084/MJHID.2015.011. eCollection 2015.
Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
Mateos MV et al. Am J Hematol. 2015 Jan 2. doi: 10.1002/ajh.23933. [Epub ahead of print].
Variation in fatigue among 6011 (long-term) cancer survivors and a normative population: a study from the population-based PROFILES registry.
Husson O et al. Support Care Cancer. 2015 Jan 6. [Epub ahead of print].
New Cancers after Autotransplantations for Multiple Myeloma.
Mahindra A et al. Biol Blood Marrow Transplant. 2014 Dec 31. pii: S1083-8791(14)01472-4. doi: 10.1016/j.bbmt.2014.12.028. [Epub ahead of print].
Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma.
Chan KL et al. Leuk Lymphoma. 2014 Dec 30:1-8. [Epub ahead of print].
Salmonella Typhimurium pneumonia in a patient with multiple myeloma.
Khan S et al. Trop Doct. 2014 Dec 24. pii: 0049475514565427. [Epub ahead of print].
Neutrophilic dermatosis: disease mechanism and treatment.
Maalouf D et al. Curr Opin Hematol. 2015 Jan;22(1):23-9. doi: 10.1097/MOH.0000000000000100.
An otherwise healthy young man presents with bilateral crvo as the first sign of hyperviscosity syndrome in the setting of new multiple myeloma.
Golesic EA et al. Retin Cases Brief Rep. 2015 Winter;9(1):38-40. doi: 10.1097/ICB.0000000000000071.
Drug-induced modulation of T lymphocytes as a potential mechanism of susceptibility to infections in patients with multiple myeloma during bortezomib therapy.
Li J et al. Cell Biochem Biophys. 2015 Jan;71(1):457-64. doi: 10.1007/s12013-014-0224-x.
Hepatitis B virus reactivation in patients with multiple myeloma receiving bortezomib-containing regimens followed by autologous stem cell transplant.
Li J et al. Leuk Lymphoma. 2015 Jan 14:1-8. [Epub ahead of print].